ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

被引：2
|
作者：
Hanamoto, Hitoshi
Morita, Yasuyoshi
Ichikawa, Motoshi
Nannya, Yasuhito
Shibayama, Hirohiko
Maeda, Yoshinobu
Hata, Tomoko
Miyamoto, Toshihiro
Kawabata, Hiroshi
Takeuchi, Kazuto
Tanaka, Hiroko
Kishimoto, Junji
Miyano, Satoru
Matsumura, Itaru
Ogawa, Seishi
Akashi, Koichi
Kanakura, Yuzuru
Mitani, Kinuko
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134483
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
    Morita, Yasuyoshi
    Nannya, Yasuhito
    Ichikawa, Motoshi
    Hanamoto, Hitoshi
    Shibayama, Hirohiko
    Maeda, Yoshinobu
    Hata, Tomoko
    Miyamoto, Toshihiro
    Kawabata, Hiroshi
    Takeuchi, Kazuto
    Tanaka, Hiroko
    Kishimoto, Junji
    Miyano, Satoru
    Matsumura, Itaru
    Ogawa, Seishi
    Akashi, Koichi
    Kanakura, Yuzuru
    Mitani, Kinuko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (05) : 659 - 668
  • [2] ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
    Yasuyoshi Morita
    Yasuhito Nannya
    Motoshi Ichikawa
    Hitoshi Hanamoto
    Hirohiko Shibayama
    Yoshinobu Maeda
    Tomoko Hata
    Toshihiro Miyamoto
    Hiroshi Kawabata
    Kazuto Takeuchi
    Hiroko Tanaka
    Junji Kishimoto
    Satoru Miyano
    Itaru Matsumura
    Seishi Ogawa
    Koichi Akashi
    Yuzuru Kanakura
    Kinuko Mitani
    International Journal of Hematology, 2022, 116 : 659 - 668
  • [3] Baseline predictors of response to treatment with darbepoetin-alpha (DA) in anemic patients with low-risk myelodysplastic syndrome (MDS)
    Gabrilove, J.
    Paquette, R.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Tomita, D.
    Lillie, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs
    Wu, Ping
    Weng, Jianyu
    Li, Minming
    Lu, Zesheng
    Deng, Chengxin
    Sun, Qihui
    Xu, Ruohao
    Geng, Suxia
    Du, Xin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (06): : 3651 - 3658
  • [5] ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia
    Machnicki, Marcin M.
    Pepek, Monika
    Solarska, Iwona
    Niesiobedzka-Krezel, Joanna
    Seferynska, Ilona
    Tybor, Joanna Gora
    Zawada, Magdalena
    Sacha, Tomasz
    Sawicki, Waldemar
    Wasilewska, Ewa
    Pruszczyk, Katarzyna
    Rydzanicz, Malgorzata
    Ploski, Rafal
    Skorski, Tomasz
    Stoklosa, Tomasz
    BLOOD, 2019, 134
  • [6] Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
    Stasi, R
    Abruzzese, E
    Lanzetta, G
    Terzoli, E
    Amadori, S
    ANNALS OF ONCOLOGY, 2005, 16 (12) : 1921 - 1927
  • [7] ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
    Ernst, Thomas
    Schoenfeld, Lioba
    Rinke, Jenny
    Hinze, Anna
    Nagel, Saskia N.
    Schaefer, Vivien
    Schenk, Thomas
    Fabisch, Christian
    Bruemmendorf, Tim H.
    Burchert, Andreas
    le Coutre, Philipp
    Krause, Stefan W.
    Saussele, Susanne
    Safizadeh, Fatemeh
    Pfirrmann, Markus
    Hochhaus, Andreas
    BLOOD, 2022, 140
  • [8] High response rate to darbopoetin alfa in "low risk" MDS: Results of a phase II study.
    Mannone, L
    Gardin, C
    Quarre, MC
    Bernard, JF
    Giraudier, S
    Rosenthal, E
    Vassilief, D
    Hamza, F
    Park, S
    Kiladjian, JJ
    Vaultier, S
    Beyne-Rouzy, M
    Cheze, S
    Voilliat, L
    Agape, P
    Dreyfus, F
    Fenaux, P
    BLOOD, 2004, 104 (11) : 24A - 24A
  • [9] Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: Exploratory analysis of baseline predictors of response.
    Gabrilove, J.
    Paquette, R.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Lam, H.
    Dreiling, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
  • [10] A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
    Pierre Fenaux
    Valeria Santini
    Maria Antonietta Aloe Spiriti
    Aristoteles Giagounidis
    Rudolf Schlag
    Atanas Radinoff
    Liana Gercheva-Kyuchukova
    Achilles Anagnostopoulos
    Esther Natalie Oliva
    Argiris Symeonidis
    Mathilde Hunault Berger
    Katharina S. Götze
    Anna Potamianou
    Hari Haralampiev
    Robert Wapenaar
    Iordanis Milionis
    Uwe Platzbecker
    Leukemia, 2018, 32 : 2648 - 2658
12345